These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33374391)

  • 1. Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges.
    Alshehri S; Imam SS; Rizwanullah M; Akhter S; Mahdi W; Kazi M; Ahmad J
    Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33374391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of Drug Delivery Technology and Nanomedicine by Using Gold Nanoparticles].
    Ozeki T; Tagami T
    Yakugaku Zasshi; 2021; 141(3):323-326. PubMed ID: 33642498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation targeted nanomedicines: Patents and applications in cancer therapy.
    Praveen TK; Gangadharappa HV; Abu Lila AS; Moin A; Mehmood K; Krishna KL; Hussain T; Alafnan A; Shakil S; Rizvi SMD
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):645-663. PubMed ID: 35405339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.
    Calatayud DG; Neophytou S; Nicodemou E; Giuffrida SG; Ge H; Pascu SI
    Front Chem; 2022; 10():830133. PubMed ID: 35494646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
    Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
    Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.
    Liu Y; Lin Z; Wang Y; Chen L; Wang Y; Luo C
    Theranostics; 2024; 14(6):2490-2525. PubMed ID: 38646646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Incorporated Nanomedicines for Cancer Therapy.
    Wu SY; Wu FG; Chen X
    Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer nanomedicine: a review of recent success in drug delivery.
    Tran S; DeGiovanni PJ; Piel B; Rai P
    Clin Transl Med; 2017 Dec; 6(1):44. PubMed ID: 29230567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imprinting of glycoproteins: From preparation to cancer theranostics.
    Ali MM; Zhu S; Amin FR; Hussain D; Du Z; Hu L
    Theranostics; 2022; 12(5):2406-2426. PubMed ID: 35265217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging theranostics to combat cancer: a perspective on metal-based nanomaterials.
    Agnihotri TG; Gomte SS; Jain A
    Drug Dev Ind Pharm; 2022 Nov; 48(11):585-601. PubMed ID: 36448770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for kidney diseases.
    Williams RM; Jaimes EA; Heller DA
    Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma.
    Vinhas R; Mendes R; Fernandes AR; Baptista PV
    Front Bioeng Biotechnol; 2017; 5():79. PubMed ID: 29326927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
    Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
    Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
    Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
    Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and challenges in the translation of cancer nanomedicines.
    Tong F; Wang Y; Gao H
    Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine(s) under the microscope.
    Duncan R; Gaspar R
    Mol Pharm; 2011 Dec; 8(6):2101-41. PubMed ID: 21974749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.